parkinsons disease - search results

Parkinson’s Disease affects all activities of patient daily living but PKG can help.

Global Kinetics aim to improve the lives of those with Parkinson’s disease with advanced medical technologies.

A clinical trial at Oxford University has found that a drug used for rheumatoid arthritis can reverse Dupuytren’s disease, if taken early on.

Jacqueline Hoogendam, JPND’s newly elected Vice-Chair and Executive Board member talks about JPND’s past and present strategies in its outreach campaign within and beyond Europe.

The death rate from Parkinson’s disease has risen by 63% in the United States, according to a new study.

Dr Rutger Zietsma – CEO at Manus Neurodynamica Ltd – and PD Dr Angela Deutschländer share their vision on earlier diagnosis and objective symptom tracking with the NeuroMotor PenTM.

Professor of Neurology Thomas Gasser, JPND’s Scientific Advisory Board Chair and Director of the Department of Neurodegenerative Diseases, shares in an interview JPND’s innovative research and collaboration efforts in the universal race against Alzheimer’s and Parkinson’s diseases.

Professor Dame Pamela Shaw explains how the National Institute for Health Research (NIHR) supports experimental medicine and translational research in neurodegenerative diseases.

A new study published in the Movement Disorders journal, has paved the way for more research into identifying markers of progression for patients in the early stages of Parkinson’s disease

National Institutes of Health scientists develop new brain disease test for the early diagnosis of Parkinson’s disease and dementia with Lewy bodies The group, led by NIH’s National Institute of Allergy and Infectious Diseases (NIAID), tested 60 cerebral spinal fluid samples, including 12 from people with Parkinson’s disease, 17 from...

Ramón Cacabelos, President of EuroEspes Biomedical Research Centre looks at conventional pharmacological treatments for Parkinson’s disease

Dr Mehis Pilv, CEO and business development lead at Genecode, discusses the strides being made in Parkinson's disease research Parkinson's disease is a slow but progressive neurodegenerative disorder. About 1% of people aged above 50 are affected worldwide. In Europe alone 1.2 million people suffer from Parkinson's disease, 127,000 of whom...

Frédéric Destrebecq, Executive Director, and Vinciane Quoidbach, Public Health and Policy Project Manager at the European Brain Council, explain the socio-economic impact of interventions and the importance of early diagnosis with regard to brain disorders… Depression, stroke, dementia, alcohol dependence, schizophrenia or anxiety will affect at least one in three...

One of JPND’s key objectives is to fortify its work in brain health partnerships in Europe to better combat the challenges of neurodegenerative disease (ND).

Research shows that a new form of non-invasive brain surgery using a focused form of ultrasound will prove invaluable for with Parkinson’s symptoms.

Professor Mogens Hørder, PPI expert, JPND’s management board member and representative of member state Denmark, discusses how Patient and Public Involvement (PPI) is at the heart of neurodegenerative disease research.

George Ordiway, a PhD student in the laboratory of Dr. Jason Tait Sanchez at Northwestern University, discusses how patterned activity in the nervous system permits a wide range of biologically relevant functions, including auditory development.

Alex Schiphorst, Science Communication and Policy Officer discusses the vital role of chemistry when it comes to the future of Europe.

Dr Gerry Morrow shares his thoughts on the current state of play when it comes to the early diagnosis of neurodegenerative disorders, and asks the questions, can we screen, and should we screen?

Naoko Tanese from New York University School of Medicine outlines their work around Huntington’s disease (HD) and new targets for therapeutic intervention